Fhhwdj86sti7masvw3ku pang

Pangaea Oncology SA

Barcelona, Barcelona, ES

Pangaea Oncology provides Molecular Diagnostics and R+D services in the field of personalized cancer treatment. Our research programs include Biomarker Discovery, Molecular Diagnostics Assays and Drug Development. Founded in 2007, we have grown rapidly to become a reference laboratory in our field and and have established client relationships with some of the largest global pharmaceutical, diagnostics and biotech companies.

Our mission is to generate a new framework of therapeutic oncology based on personalized models, and incorporate this strategy into standard medical practice.

For patient care, we are the molecular diagnostics laboratory of choice for the Dr Rosell Oncology Institute (IOR) and the reference laboratory for cancer testing for the Quirón Dexeus University Hospital, Barcelona. Through these partnerships we gain valuable insights which inform our R+D programs.

Our Chief Scientific Officer is... Show more »

Pangaea Oncology provides Molecular Diagnostics and R+D services in the field of personalized cancer treatment. Our research programs include Biomarker Discovery, Molecular Diagnostics Assays and Drug Development. Founded in 2007, we have grown rapidly to become a reference laboratory in our field and and have established client relationships with some of the largest global pharmaceutical, diagnostics and biotech companies.

Our mission is to generate a new framework of therapeutic oncology based on personalized models, and incorporate this strategy into standard medical practice.

For patient care, we are the molecular diagnostics laboratory of choice for the Dr Rosell Oncology Institute (IOR) and the reference laboratory for cancer testing for the Quirón Dexeus University Hospital, Barcelona. Through these partnerships we gain valuable insights which inform our R+D programs.

Our Chief Scientific Officer is international expert in translational cancer research Dr Rafael Rosell, and our Pathology Unit is led by renowned expert pathologist Dr Santiago Ramon y Cajal. The Pangaea team is composed of prestigious clinical and research professionals, combining expertise in preclinical cancer research with extensive experience in biomarker discovery, drug development and diagnostic tools with a special focus on liquid biopsies.

Recent Publications

  • Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. The Lancet Respiratory Medicine 10 April 2017 Epub ahead of print.
  • Santarpia M, Karachaliou N, Rosell R. Beyond platinum treatment for NSCLC: what does the future hold? Expert Rev Anticancer Ther. 2017 Apr;17(4):293-295
  • Umberto Malapelle, Clara Mayo de-Las-Casas, Danilo Rocco, Monica Garzon, Pasquale Pisapia, Nuria Jordana-Ariza, Maria Russo, Roberta Sgariglia, Caterina De Luca, Francesco Pepe, Alejandro Martinez-Bueno, Daniela Morales-Espinosa, María González-Cao, Niki Karachaliou, Santiago Viteri Ramirez, Claudio Bellevicine, Miguel Angel Molina-Vila, Rafael Rosell and Giancarlo Troncone. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. British Journal of Cancer 116, 802-810 (14 March 2017)
  • Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A. Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. Prat A. Clin Chem. 2017 Mar;63(3):751-760
  • Karachaliou N, Sosa AE, Barron FB, Gonzalez Cao M, Santarpia M, Rosell R. Pharmacological management of relapsed/refractory NSCLC with chemical drugs. Expert Opin Pharmacother. 2017 Feb;18(3):295-304
  • Karachaliou N, Lazzari C, Verlicchi A, Sosa AE, Rosell R. HER3 as a Therapeutic Target in Cancer. BioDrugs. 2017 Feb;31(1):63-73
« Show less

Pangaea Oncology SA has not listed any services.

Immuno-oncology Assays
Price on request
Request a quote for more information about this service.
Cell Lines
Price on request
Request a quote for more information about this service.
Biomarker Discovery
Price on request
Request a quote for more information about this service.
Immunohistochemistry (IHC)
Price on request
Request a quote for more information about this service.
Mutation Analysis
Price on request
Request a quote for more information about this service.
RNA Expression Profiling
Price on request
Request a quote for more information about this service.
Fluorescence in situ Hybridization (FISH)
Price on request
Request a quote for more information about this service.
Targeted Sequencing
Price on request
Request a quote for more information about this service.
Next Generation Sequencing
Price on request
Request a quote for more information about this service.
Liquid Biopsy
Price on request

For certain cancers, we have developed highly sensitive and specific diagnostic tests using alternative biosources such as blood. This overcomes the challenges associated with obtaining sufficient tumor material for genetic analyses and makes serial treatment monitoring and early detection of therapy resistance a reality in... Show more »

For certain cancers, we have developed highly sensitive and specific diagnostic tests using alternative biosources such as blood. This overcomes the challenges associated with obtaining sufficient tumor material for genetic analyses and makes serial treatment monitoring and early detection of therapy resistance a reality in personalized cancer treatment. We are one of the leading European providers in the field of liquid biopsies and the first pharmacogenomics laboratory in Spain to be accredited, by the National Accreditation Body (ENAC), ISO 15189, to perform genetic testing for cancer patients in liquid biopsy (serum/plasma) samples (EGFR mutations, exon 19, 20 [T790M] and 21; KRAS, exon 12-13; BRAF V600E) (nº750 / LE15156 Annex 7).

« Show less
Histopathological Examination
Price on request

We perform pathological evaluation of tumors via bright field to confirm diagnoses. Our highly accurate microdissection equipment enables dissection of specific cells, ensuring maximum efficiency in subsequent tests.

We perform pathological evaluation of tumors via bright field to confirm diagnoses. Our highly accurate microdissection equipment enables dissection of specific cells, ensuring maximum efficiency in subsequent tests.

« Show less
Ask A Question Find what you're looking for? If not, you can ask this lab a question:

Pangaea Oncology SA has not received any ratings.

Be the first to endorse Pangaea Oncology SA

Endorse this lab